Abstracts of student sessions

Plenary sessions ........................................... 127
Oral sessions I ........................................... 137
  Biochemistry ........................................... 139
  Cardiology ............................................ 147
  Immunology ........................................... 155
  Obstetrics, Gynaecology & Reproductive Health ........................................... 163
  Oncology ............................................. 171
  Otorhinolaryngology, Head-Neck Surgery & Ophthalmology + Breaking News ........................................... 179
Pathology ................................................ 185
Pharmacology I ........................................... 193
Public Health ........................................... 201
Surgery .................................................. 209
Vascular Medicine ........................................ 217
Oral sessions II ........................................... 225
  Biomaterials ........................................... 227
  Cell Biology ........................................... 235
  Cerebro- & Cardiovascular Medicine ........................................... 243
  Infectious Disease .................................... 251
  Movement Sciences .................................... 259
  Nephrology ........................................... 267
  Neurology ............................................ 275
  Oncology II .......................................... 283
  Paediatrics ........................................... 291
  Pharmacology II ...................................... 299
  Psychiatry ............................................ 307
Poster sessions I ........................................... 315
  Cell Biology & Medical Physiology ........................................... 317
  Dentistry & Dental Surgery ........................................... 327
  Epidemiology & Cardiology ........................................... 335
  General Surgery ....................................... 345
  Geriatrics & Pathology ................................... 353
  Gynaecology .......................................... 361
  Imaging & Radiotherapy ................................... 371
  Medical Microbiology .................................... 379
  Nephrology & Urology .................................... 387
  Neurology I ............................................ 395
  Oncology ............................................. 405
  Pharmacology I ........................................ 415

Psychiatry ............................................. 425
Public Health .......................................... 435
Poster sessions II ........................................... 443
  Cardiology & Pulmonary Disease ........................................... 445
  Dermatology & Biomaterials ........................................... 453
  Endocrinology ......................................... 463
  Epidemiology .......................................... 471
  Genetics .............................................. 479
  Immunology .......................................... 489
  Infectious Disease ...................................... 499
  Internal Medicine ....................................... 509
  Neurology II .......................................... 519
  Obstetrics & Reproductive Health ........................................... 525
  Orthopaedics & Gastrointestinal Medicine ........................................... 535
  Pharmacology II ........................................ 545
  Pharmacology III ....................................... 555
  Psychiatry & Public Health ........................................... 563
Index of abstracts ........................................ 572

Postscript
  Research institutes, magazines & funds ........................................... 576
  Sponsors ............................................. 578
  Special thanks ........................................ 580
  Committee of Recommendation ........................................... 582
Pharmacology II

Chair
Leo Deelman PhD

Presenters
Afshari, K. (Khashayar)
Dewi, D.P.K. (Dea)
Hamidianjahromi, A. (Anahid)
Putri, A. (Ayunda)
Tootoonchi, Z. (Zahra)
Tripathi, M. (Mudrika)
Yaftian, R. (Rahele)
Zaręba, Ł. (Łukasz)
Protective effect of Metformin against spinal cord injury in male rats

Afshari, K. (Khashayar)1, Ebrahimi, M. (Mohammad Ali)2, Haj-Mirzaian, A. (Arvin)3, Ramezanzadeh, K. (Kiana)3, Dehpour, A. (Ahmad Reza)2

1 Tehran University of Medical Sciences, Department of Pharmacology, School of medicine, Tehran, Iran, Islamic Republic of
2 Tehran University of Medical Sciences, Department of Pharmacology, Tehran, Iran, Islamic Republic of
3 Shahid beheshti university of medical sciences, Department of pharmacology, Tehran, Iran, Islamic Republic of

Introduction
Spinal Cord Injury (SCI) is a disabling disease that happens due to damage spinal cord resulting in loss of cord’s motor, sensory and autonomic functions. Studies have shown that Metformin is an inhibitor of mammalian Target Of Rapamycin (mTOR) and this inhibition leads to attenuation of neuronal damage and locomotor impairment in spinal cord injury. Our objective is to investigate the effect of metformin on repair of rat SCI through inhibition of mTOR.

Material & methods
A total of forty-five male rats (weight 250-300g) were used in this study. Experiments were performed to determine a dose of metformin that effectively improves locomotor and sensory scores in rats with SCI. Therefore, rats received different doses of Metformin (10, 50, 100 mg/kg intraperitoneal) or saline 1 hour before surgery. SCI was induced by compressing the T9 spinal segment with an aneurysmal clip for 60 seconds in anesthetized rats. After the surgery during four weeks of study Tail flick latency (TFL) and BBB (Basso-Beattie-Bresnahan) locomotor score were evaluated. Locomotor scores were determined at 1, 3, 5, 7, 14, 21 and 28 days after SCI. Spinal histopathologies were examined 30 days after SCI.

Results
Our preliminary results showed an overall significant improvement in locomotor scores of rats with SCI was observed. Within-Subjects repeated measures (P =0.004,) is observed. In the Between-Subjects analysis, medium dose metformin monotherapy (metformin 50 mg/kg) had a superior impact compared to low- and high-dose metformin (10 mg/kg and 50 mg/kg, respectively) and control saline on increasing locomotor scores at different intervals post SCI.

Conclusion
Studies have shown inhibition of mTOR reduces neuronal damage and locomotor impairment after spinal cord injury also producing neuroprotective effects and reducing secondary damage at the lesion. Although the effects of Metformin, a known inhibitor of mTOR which is also a safe known drug for diabetes, has never been studied in spinal cord injury. In this study we evaluated the therapeutic effects of metformin in SCI of rats. Results show a presumably mTor inhibition induced improvement of locomotion through histopathologically demonstrated neuroprotection and damage reduction. Metformin also showed to have protective effects against neuropathic pain which is a sensory complication of SCI.